NovaBridge Heads to Leerink with Key Pipeline Data in Focus

ROCKVILLE, MD – March 02, 2026 – As the biotechnology world turns its eyes toward the upcoming Leerink Partners 2026 Global Healthcare Conference, one company, NovaBridge Biosciences (Nasdaq: NBP), is poised to capture significant attention. The company announced its management will participate in a fireside chat on March 11, an event that serves as a critical platform for a clinical-stage firm with two high-stakes assets advancing through pivotal trials.

For investors and industry observers, the presentation is more than a routine update. It's an opportunity to gauge the momentum of a company that has recently rebranded—changing its name from I-Mab and its ticker from IMAB in late 2025—and is now pushing forward with a focused pipeline in oncology and ophthalmology. With key clinical data recently released and major studies underway, the discussions at Leerink could set the tone for NovaBridge's valuation and strategic trajectory for the year ahead.

The Investor Spotlight at a Premier Conference

Participation at the Leerink Partners conference is a significant milestone for any biotech, offering a direct line to institutional investors, financial analysts, and potential partners. For NovaBridge, the timing is particularly crucial. The company's stock (NBP) has shown resilience, outperforming both the US Biotechs industry and the broader market over the past year. With weekly volatility decreasing, the stock has demonstrated a trend toward stability, and a recent "Strong Buy" consensus from some analysts with a $9.00 price target suggests high expectations.

This upcoming presentation offers a forum to build on that momentum. The management team, likely led by CEO Sean Fu, PhD, MBA, and Chief Medical Officer Phillip Dennis, MD, PhD, will be expected to articulate a clear vision for the company's path forward. Key discussion points will inevitably revolve around the company's financial health—it remains unprofitable, as is common for biotechs in the development phase—and its strategy for funding its ambitious clinical programs through to potential commercialization. Recent actions, such as the announced open market share purchases by Executive Chairman Fu Wei, signal internal confidence, a message the company will be keen to reinforce.

Givastomig: A Potential Best-in-Class Cancer Therapy

Central to NovaBridge's story is its lead oncology candidate, givastomig. This bispecific antibody, which targets both Claudin 18.2 on tumor cells and the 4-1BB receptor on T cells, is being developed to treat gastric cancer and other gastrointestinal malignancies. The company is advancing the drug based on highly encouraging results from a Phase 1b study in first-line metastatic gastric cancer.

The recently announced data was robust. In combination with chemotherapy and an anti-PD-1 checkpoint inhibitor, givastomig demonstrated an overall response rate (ORR) as high as 77%. Perhaps more importantly, the therapy showed efficacy across a wide range of Claudin 18.2 expression levels, a key potential differentiator from competitors like zolbetuximab (Vyloy), which is restricted to patients with high expression. This suggests givastomig could address a much larger patient population within the estimated $12 billion market for Claudin 18.2-directed therapies.

Furthermore, the durability of the response was impressive, with a median progression-free survival (PFS) of 16.9 months reported in one cohort. The safety profile was described as manageable and comparable to the current standard of care, a critical factor for any new oncology agent. NovaBridge has already acted on this positive data, initiating a global, randomized Phase 2 study in the first quarter of 2026. Investors at the Leerink conference will be listening intently for any further details on the trial's design, enrollment progress, and the timeline for topline results, which are currently anticipated in 2027.

A Dual-Pronged Attack on Vision Loss with VIS-101

While oncology often grabs headlines, NovaBridge's ophthalmology asset, VIS-101, represents another significant pillar of its pipeline. Developed through its majority-owned subsidiary Visara, Inc., VIS-101 is a bifunctional biologic targeting both VEGF-A and ANG-2, two key pathways involved in retinal vascular diseases like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

The market for these conditions is mature and highly competitive, dominated by anti-VEGF therapies like Eylea and Lucentis. However, a major unmet need persists: the significant treatment burden associated with frequent eye injections. The industry trend is moving toward more durable therapies, as exemplified by the success of dual-targeting agents like Vabysmo, which also inhibits VEGF and Ang-2.

VIS-101 is positioned to compete in this next wave of innovation. By blocking two validated targets, it aims to provide more potent and longer-lasting effects, potentially reducing the number of injections patients need per year. According to the company, VIS-101 is currently completing a randomized, dose-ranging Phase 2a study for wet AMD. The upcoming conference provides a perfect opportunity for management to share updates on this trial's status or perhaps provide a first glimpse at the data. Any indication of a competitive durability profile would be a major catalyst for the program and for NovaBridge's valuation.

The Platform Play: A Modern Approach to Drug Development

Underpinning these clinical assets is NovaBridge's overarching strategy as a "global biotechnology platform company." This "hub-and-spoke" model is designed to accelerate drug development by combining business development expertise with agile clinical execution. The company actively identifies promising external assets and builds structures around them to advance them rapidly.

The formation of Visara, Inc. to house VIS-101 is a prime example of this model in action. By establishing a dedicated subsidiary, NovaBridge can focus resources and expertise on the asset while maintaining majority ownership. The recent appointment of Visara co-founder Dr. Emmett T. Cunningham, Jr. to NovaBridge's board as Vice Chairman further validates this approach, bringing deep ophthalmology and venture creation experience into the parent company's leadership.

This strategy allows NovaBridge to build a diversified pipeline without relying solely on internal discovery. It is a capital-efficient approach that leverages external innovation. During the fireside chat, management will likely highlight this differentiated business model as a key strength, explaining how it enables them to de-risk development and rapidly progress transformative therapies toward patients. Investors will be keen to understand how this platform will be leveraged for future growth and what new assets might be brought into the fold. As the company prepares for its moment on the Leerink stage, it carries the weight of high expectations, but also the promise of a pipeline and a strategy designed for the modern era of biotechnology.